Latest Diabetes mellitus type 2 Stories
RIDGEFIELD, Conn. and INDIANAPOLIS, March 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S. JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines - the...
SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is participating in the fifth annual international Rare Disease Day to demonstrate the Company's support for patients and families who are impacted by rare diseases. Celebrated around the world today, Rare Disease Day aims to raise awareness of the more than 7,000 known rare diseases and the effects of these diseases on patients' lives, and to provide a platform of unity for...
BOSTON, Feb. 28, 2012 /PRNewswire/ -- The Food and Drug Administration advisory panel voted on Wednesday, Feb. 22, 2012, in favor of recommending that the FDA approve the prescription obesity drug Qnexa. If approved, this will be the first time in more than a decade that a prescription weight-loss medication receives FDA approval. This landmark recommendation prompted the 2012 Cardiometabolic Health Congress (CMHC) expert faculty to weigh in on the implications of the potential...
CINCINNATI, Feb. 27, 2012 /PRNewswire/ -- Health care professionals tend to underestimate a patient's willingness to discuss their weight and treatment options(1). To help address this communication gap, the American College of Physicians Foundation has developed a Patient Centered Education guidebook and DVD called "Live Healthier - Weight Loss Options for Treating Obesity." This tool was supported by funding from Ethicon Endo-Surgery, Inc., (EES), a leader in bariatric and...
WASHINGTON, Feb. 23, 2012 /PRNewswire-USNewswire/ -- Members of the Obesity Care Continuum (OCC) are pleased with the FDA's Advisory Committee near unanimous vote to approve QNEXA, a new drug to treat those affected by obesity and obesity-related co-morbidities, such as Type 2 diabetes, hypertension and more. "The robust discussion by the panel surrounding both the risks and benefits of new obesity drugs is both refreshing and powerful," said Obesity Action Coalition (OAC)...
SAN DIEGO and DUBLIN, Feb. 13, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that BYDUREON(TM) (exenatide extended-release for injectable suspension) is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved BYDUREON, the first and only once-weekly treatment for type 2 diabetes, on Jan. 27, 2012 as an adjunct to diet and exercise to improve glycemic control in...
ACP issues new clinical practice guideline for drug treatment of type 2 diabetes The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have failed to adequately improve high blood sugar. ACP also recommends that clinicians add a second drug to metformin when treatment with metformin and lifestyle changes fail to control...
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control...
WARSAW, Poland, January 30, 2012 /PRNewswire/ -- Global Managed-Care Offering to Help Bring Down Treatment Costs for 366 Million Diabetics Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin...
SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON(TM) (exenatide extended-release for injectable suspension) - the first once-weekly treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...
